MedTrace Logo

Extension Study of Participants From SPG302-ALZ-101

NCT06833281 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-12-18

No results posted yet for this study

Summary

This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALZ-101 with mild to moderate Alzheimer's Disease (AD)

Conditions

Interventions

DRUG

SPG302

small synthetic molecule

Sponsors & Collaborators

  • Spinogenix

    lead INDUSTRY

Principal Investigators

  • Lauren Priest, MBBS · Flinders Medical Center, Adelaide, SA, Australia

  • Brew Brew, MBBS, MD, DSC · St Vincents Hospital, Sydney, NSW, Australia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-25
Primary Completion
2025-07-30
Completion
2025-10-09

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06833281 on ClinicalTrials.gov